Apple Reports Results… And Novo Nordisk’s Obesity Drug Price Cut 5/2/24
CNBC's "Fast Money"
00:00
Biopharma Market Analysis and Competitive Landscape
Discussion on AMGEN's earnings report, decision to discontinue a weight loss pill, and advance an injectable obesity treatment to Phase 3 trial. Speculation on upcoming drug releases, market impact, and comparison to competitors Novo and Lily.
Play episode from 19:21
Transcript
